<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103605</url>
  </required_header>
  <id_info>
    <org_study_id>D5161R00017</org_study_id>
    <nct_id>NCT05103605</nct_id>
  </id_info>
  <brief_title>Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations</brief_title>
  <acronym>POSITHES</acronym>
  <official_title>Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is an observational multicenter study. A cross-sectional descriptive study of patients&#xD;
      with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation&#xD;
      treated by any first line therapy will be used to identify cohort with a prospective&#xD;
      follow-up of patients initiating a treatment by osimertinib in first line&#xD;
&#xD;
        -  A cross-sectional descriptive study of all patients with locally advanced or metastatic&#xD;
           NSCLC with activating EGFR mutation treated by any first line therapy will be collected&#xD;
           at the study participating sites. The study which is transversal will allow to&#xD;
           characterize the population of patients with locally advanced or metastatic NSCLC with&#xD;
           activating EGFR mutation treated in first line, the day of first line initiation.&#xD;
&#xD;
        -  Additionally, a prospective study targeting a cohort of patients focusing on patients&#xD;
           with locally advanced or metastatic NSCLC with activating EGFR mutation initiating a&#xD;
           treatment by osimertinib in first line will be conducted to address describe in real&#xD;
           life conditions the 36-months overall survival, patients baseline characteristics,&#xD;
           disease evolution, sequencing and treatment patterns, and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational multicenter study combining a descriptive cross-sectional survey and&#xD;
      a prospective cohort design to address the study objectives.&#xD;
&#xD;
      Part A is a prospective study targeting a cohort of patients focusing on patients with&#xD;
      locally advanced or metastatic NSCLC with activating EGFR mutation initiating a treatment by&#xD;
      osimertinib in first line will be conducted to address the primary objective of this study&#xD;
      and remaining secondary objectives.&#xD;
&#xD;
      Part B is an additional descriptive cross-sectional survey of all patients with locally&#xD;
      advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy&#xD;
      will be collected at the study participating sites. The study part which is cross sectional&#xD;
      will allow to characterize the population of patients with locally advanced or metastatic&#xD;
      NSCLC with activating EGFR mutation treated in first line, the day of first line initiation.&#xD;
&#xD;
      Both studies will be initiated at the same time (depending on osimertinib reimbursement in&#xD;
      France - expected on October 2020). Part A will have an enrolment period of approximately 18&#xD;
      months and a follow-up period of 36 months. Part B will have an enrolment period of 12&#xD;
      months.&#xD;
&#xD;
      For Part A, patients must be newly treated in first line and the index date will be the day&#xD;
      of first line treatment initiation. Patients will be followed-up for all routine visits&#xD;
      recorded until time to second progression. After the relapse of second line therapy, patients&#xD;
      will be followed-up every 6 months for overall survival only until 36 months.&#xD;
&#xD;
      For Part B, patients newly diagnosed with locally advanced or metastatic NSCLC who are&#xD;
      treatment naive or patients who were diagnosed at an earlier stage but have progressed to&#xD;
      metastatic NSCLC during the selection period will be included.&#xD;
&#xD;
      Patients will be followed up from enrolment in part A until death, loss to follow-up,&#xD;
      withdrawal of consent or study end date, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>36-months overall survival defined as time from index date until death from any cause</description>
  </primary_outcome>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Single arm treated by osimertinib</description>
    <other_name>TAGRISSO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study combining a descriptive cross-sectional survey (part B) and a prospective cohort&#xD;
        design (part A).&#xD;
&#xD;
        Patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) with&#xD;
        activating EGFR mutation initiating a treatment by osimertinib in first line (Population A)&#xD;
&#xD;
        Patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by&#xD;
        any first line therapy (population B)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Descriptive cross-sectional survey (Population B)&#xD;
&#xD;
               -  Adult patients (â‰¥ 18 years old),&#xD;
&#xD;
               -  Patients newly treated in first line (1L) for locally advanced or metastatic&#xD;
                  NSCLC,&#xD;
&#xD;
               -  Patients with activating EGFR mutation-positive,&#xD;
&#xD;
               -  Patient informed and not opposed to these data collection.&#xD;
&#xD;
          -  Prospective cohort (Population A)&#xD;
&#xD;
               -  Patient meeting part B inclusion criteria,&#xD;
&#xD;
               -  Patients newly treated in 1L by osimertinib,&#xD;
&#xD;
               -  Patient with common EGFR mutation-positive (exon 19 deletion or L858R mutation,&#xD;
                  alone or co-occuring with other EGFR mutations).&#xD;
&#xD;
        Exclusion Criteria (Population A):&#xD;
&#xD;
          -  Patients enrolled in interventional clinical trials (first line treatment for a NSCLC)&#xD;
             during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jean-Bernard Auliac</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Creteil, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aix En Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bourg En Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Epagny METZ Tessy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evreux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Pierre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-gregoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villefranche-sur-saone</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

